86 related articles for article (PubMed ID: 7873181)
1. Long-term episomal gene delivery in human lymphoid cells using human and avian adenoviral-assisted transfection.
Kelleher ZT; Vos JM
Biotechniques; 1994 Dec; 17(6):1110-7. PubMed ID: 7873181
[TBL] [Abstract][Full Text] [Related]
2. Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells.
Mũcke S; Polack A; Pawlita M; Zehnpfennig D; Massoudi N; Bohlen H; Doerfler W; Bornkamm G; Diehl V; Wolf J
Gene Ther; 1997 Feb; 4(2):82-92. PubMed ID: 9081710
[TBL] [Abstract][Full Text] [Related]
3. Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.
Suzuki T; Piche A; Kasono K; Xiang J; Gomez-Navarro J; Moriuchi S; Krisky DM; Oligino T; Glorioso JC; Curiel TJ; Curiel DT
Biochem Biophys Res Commun; 1998 Nov; 252(3):686-90. PubMed ID: 9837767
[TBL] [Abstract][Full Text] [Related]
4. An enhanced EBNA1 variant with reduced IR3 domain for long-term episomal maintenance and transgene expression of oriP-based plasmids in human cells.
Wendelburg BJ; Vos JM
Gene Ther; 1998 Oct; 5(10):1389-99. PubMed ID: 9930345
[TBL] [Abstract][Full Text] [Related]
5. An ovine adenovirus vector lacks transforming ability in cells that are transformed by AD5 E1A/B sequences.
Xu ZZ; Nevels M; MacAvoy ES; Lockett LJ; Curiel D; Dobner T; Both GW
Virology; 2000 Apr; 270(1):162-72. PubMed ID: 10772988
[TBL] [Abstract][Full Text] [Related]
6. Efficient foreign gene expression in Epstein-Barr virus-transformed human B-cells.
Curiel TJ; Cook DR; Bogedain C; Jilg W; Harrison GS; Cotten M; Curiel DT; Wagner E
Virology; 1994 Feb; 198(2):577-85. PubMed ID: 8291240
[TBL] [Abstract][Full Text] [Related]
7. Construction of avian adenovirus CELO recombinants in cosmids.
François A; Eterradossi N; Delmas B; Payet V; Langlois P
J Virol; 2001 Jun; 75(11):5288-301. PubMed ID: 11333910
[TBL] [Abstract][Full Text] [Related]
8. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
Nilsson T; Sjöblom A; Masucci MG; Rymo L
Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
[TBL] [Abstract][Full Text] [Related]
9. Genetic design of an optimized packaging cell line for gene vectors transducing human B cells.
Hettich E; Janz A; Zeidler R; Pich D; Hellebrand E; Weissflog B; Moosmann A; Hammerschmidt W
Gene Ther; 2006 May; 13(10):844-56. PubMed ID: 16421600
[TBL] [Abstract][Full Text] [Related]
10. Stable transduction of actively dividing cells via a novel adenoviral/episomal vector.
Leblois H; Roche C; Di Falco N; Orsini C; Yeh P; Perricaudet M
Mol Ther; 2000 Apr; 1(4):314-22. PubMed ID: 10933949
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus type 5 persisting in human lymphocytes is unlikely to be involved in immortalization of lymphoid cells by fusion with cytoplasts or by transfection with DNA of mouse L cells.
Abken H; Bützler C; Willecke K
Anticancer Res; 1987; 7(4A):553-8. PubMed ID: 2959195
[TBL] [Abstract][Full Text] [Related]
12. Engineering a mini-herpesvirus as a general strategy to transduce up to 180 kb of functional self-replicating human mini-chromosomes.
Sun TQ; Livanos E; Vos JM
Gene Ther; 1996 Dec; 3(12):1081-8. PubMed ID: 8986434
[TBL] [Abstract][Full Text] [Related]
13. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
14. Novel recombinant adenovirus type 41 vector and its biological properties.
Lu ZZ; Zou XH; Dong LX; Qu JG; Song JD; Wang M; Guo L; Hung T
J Gene Med; 2009 Feb; 11(2):128-38. PubMed ID: 19097028
[TBL] [Abstract][Full Text] [Related]
15. Latent membrane protein 1 of Epstein-Barr virus plays an important role in the serum starvation resistance of Epstein-Barr virus-immortalized B lymphocytes.
Park CH; Kim HR; Kim J; Jang SH; Lee KY; Chung GH; Jang YS
J Cell Biochem; 2004 Mar; 91(4):777-85. PubMed ID: 14991769
[TBL] [Abstract][Full Text] [Related]
16. Improved gene expression pattern using Epstein-Barr virus (EBV)-based plasmid and cationic emulsion.
Min KA; Lee SK; Kim CK
Biomaterials; 2005 Mar; 26(9):1063-70. PubMed ID: 15369695
[TBL] [Abstract][Full Text] [Related]
17. [The viral genome status studied under the conditions of a mixed infection in lymphoblastoid cells by adenovirus and the Epstein-Barr virus].
Nosach LN; Diachenko NS; Povnitsa OIu; Smirnova IA; Kishinskaia EG; Butenko ZA; Panasenko GV
Tsitol Genet; 1998; 32(4):82-8. PubMed ID: 9813890
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-derived vectors for transient and stable expression of recombinant proteins.
Cachianes G; Ho C; Weber RF; Williams SR; Goeddel DV; Leung DW
Biotechniques; 1993 Aug; 15(2):255-9. PubMed ID: 8396947
[TBL] [Abstract][Full Text] [Related]
19. Highly efficient gene transfer into murine liver achieved by intravenous administration of naked Epstein-Barr virus (EBV)-based plasmid vectors.
Cui FD; Kishida T; Ohashi S; Asada H; Yasutomi K; Satoh E; Kubo T; Fushiki S; Imanishi J; Mazda O
Gene Ther; 2001 Oct; 8(19):1508-13. PubMed ID: 11593364
[TBL] [Abstract][Full Text] [Related]
20. Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes.
Saeki Y; Wataya-Kaneda M; Tanaka K; Kaneda Y
Gene Ther; 1998 Aug; 5(8):1031-7. PubMed ID: 10326025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
